ImmunityBio
IBRX
146 hedge funds and large institutions have $89.2M invested in ImmunityBio in 2023 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 40 increasing their positions, 42 reducing their positions, and 26 closing their positions.
27% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 26
5% more funds holding
Funds holding: 139 → 146 (+7)
4% more call options, than puts
Call options by funds: $1.32M | Put options by funds: $1.27M
5% less repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 42
1.61% less ownership
Funds ownership: 12.21% → 10.6% (-1.6%)
65% less capital invested
Capital invested by funds: $256M → $89.2M (-$167M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$18M |
| 2 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$4.9M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$3.41M |
| 4 |
Millennium Management
New York
|
+$1.62M |
| 5 |
Squarepoint
New York
|
+$1.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$38.6M |
| 2 |
State Street
Boston,
Massachusetts
|
-$12.7M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$2.56M |
| 4 |
Goldman Sachs
New York
|
-$2.48M |
| 5 |
Rafferty Asset Management
New York
|
-$2.39M |
IBRX Hedge Fund Activity: Q1 2023 in Review
146 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q1 2023, worth a combined $89.2M — down 65% from $256M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new IBRX positions and 26 closed out — a net gain of 7 holders — while 40 added to existing stakes and 42 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $18M. The largest seller was CVI Holdings, exiting entirely with an estimated $38.6M sold.
- 146 institutional investors held ImmunityBio (IBRX) as of Q1 2023, up from 139 in Q4 2022.
- Funds reported $89.2M of ImmunityBio stock for Q1 2023, down 65% quarter-over-quarter.
- 33 funds opened new ImmunityBio positions in Q1 2023 and 26 closed out, a net change of +7 holders.
- The largest ImmunityBio buyer in Q1 2023 was Armistice Capital, an estimated $18M added.
- The largest ImmunityBio seller in Q1 2023 was CVI Holdings, an estimated $38.6M sold.
Based on aggregated 13F filings for Q1 2023.